Shing Chung Hin, Wang Fengfeng, Lam Pui Ming, Tsui Omar Wai Kiu, Chan Timmy Chi Wing, Wong Stanley Sau Ching
Department of Anaesthesiology, The University of Hong Kong, Hong Kong, Hong Kong.
Laboratory and Clinical Research Institute for Pain, The University of Hong Kong, Hong Kong, Hong Kong.
Reg Anesth Pain Med. 2025 Jul 23. doi: 10.1136/rapm-2025-106583.
Adding liposomal bupivacaine to brachial plexus block may improve postoperative analgesia after upper limb surgery.
This study aimed to assess the postoperative analgesic efficacy of adding liposomal bupivacaine to brachial plexus block compared with non-liposomal local anesthetic.
A systematic literature search was conducted in PubMed, Web of Science, EMBASE, ClinicalTrials.gov, and the Cochrane Library up to June 30, 2024. Randomized controlled trials (RCTs) that evaluated the postoperative pain scores in patients who received liposomal bupivacaine via brachial plexus block were identified. The primary outcome was resting pain scores (Numerical Rating Scale, 0-10) at 24 hours after nerve block injection derived from the random effects model. A mean difference (MD) of 1/10 was considered to represent a minimal clinically important difference in pain scores. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework was applied to examine the level of evidence.
21 RCTs (1478 participants) were included. Liposomal bupivacaine was associated with statistically significant reduction in resting pain scores at 24 hours after nerve block injection compared with non-liposomal local anesthetic (MD=-1.04, 95% CI=-1.54 to -0.53, p<0.001, 95% prediction interval=-3.05 to 0.98). This was associated with significant heterogeneity (Q=107, p<0.001, I²=81%, tau=1.0, 95% CI=0.42 to 2.07) and a low-GRADE rating. Liposomal bupivacaine was also associated with a statistically significant reduction in resting pain scores at 48 hours and 72 hours. Opioid consumption at 0-24 hours, 25-48 hours and 49-72 hours was lower in the liposomal bupivacaine group with statistical significance (p values <0.05). Liposomal bupivacaine was associated with a lower incidence of nausea.
There is low-level evidence that liposomal bupivacaine in brachial plexus block may reduce pain intensity after upper limb surgery, but the clinical significance may be limited.
在臂丛神经阻滞中添加脂质体布比卡因可能会改善上肢手术后的术后镇痛效果。
本研究旨在评估与非脂质体局部麻醉药相比,在臂丛神经阻滞中添加脂质体布比卡因的术后镇痛效果。
截至2024年6月30日,在PubMed、科学网、EMBASE、ClinicalTrials.gov和Cochrane图书馆进行了系统的文献检索。确定了评估通过臂丛神经阻滞接受脂质体布比卡因的患者术后疼痛评分的随机对照试验(RCT)。主要结局是神经阻滞注射后24小时的静息疼痛评分(数字评分量表,0-10),采用随机效应模型得出。疼痛评分中1/10的平均差(MD)被认为代表临床上最小的重要差异。应用推荐分级评估、制定和评价(GRADE)框架来审查证据水平。
纳入21项RCT(1478名参与者)。与非脂质体局部麻醉药相比,脂质体布比卡因在神经阻滞注射后24小时静息疼痛评分的降低具有统计学意义(MD=-1.04,95%CI=-1.54至-0.53,p<0.001,95%预测区间=-3.05至0.98)。这与显著的异质性相关(Q=107,p<0.001,I²=81%,tau=1.0,95%CI=0.42至2.07)以及低等级评分。脂质体布比卡因在48小时和72小时时静息疼痛评分的降低也具有统计学意义。脂质体布比卡因组在0-24小时、25-48小时和49-72小时的阿片类药物消耗量较低,具有统计学意义(p值<0.05)。脂质体布比卡因与恶心发生率较低相关。
有低质量证据表明,臂丛神经阻滞中的脂质体布比卡因可能会降低上肢手术后的疼痛强度,但临床意义可能有限。